The company can now begin the enrollment process for its PROACTIVE-HF 2 clinical trial, which will focus on treating patients with NYHA class II heart failure. 

The new radiotracer flurpiridaz is poised to make a major impact on nuclear cardiology. Timothy Bateman, MD, co-director of the cardiovascular radiologic imaging program at Saint Luke's Mid America Heart Institute, shared details on the tracer in a new interview. 

The subcutaneous administration of CBD could make a significant impact on patient outcomes, according to new findings presented at the Heart Failure Society of America's annual meeting in Cleveland.

Researchers explored data from the first 10 patients treated with a new self-expanding TAVR device from KOKA Lifesciences. After 30 days, there were no patient deaths and only one adverse event.

The American College of Cardiology, Society for Cardiovascular Angiography and Interventions and Society of Thoracic Surgeons raised the issue, which is related to the billing of transcatheter heart procedures such as TAVR. 

Preventing sudden cardiac arrest involves managing risk factors such as hypertension, hyperlipidemia and diabetes. We spoke to Christine Albert, MD, about this and much more at ESC 2023.

The American Heart Association has developed an updated strategy for the prevention and management of cardiovascular disease. A newly defined health condition, cardiovascular-kidney-metabolic syndrome, sits at the center of that strategy. 

Cardiac CT has been evolving rapidly in recent years. Brian Ghoshhajra, MD, outlined some of the main trends he has seen at the 2023 annual meeting of the Society of Cardiovascular Computed Tomography.